Insiders · Profile

Douglas Earl Martin

SVP, General Counsel at Allogene Therapeutics. Filing since 3 Feb 2025. CIK 0001362155

Company

Date

Role

Action

Shares

Amount

Of holding

ALLO Allogene Therapeutics, Inc.

21 Aug 2026

SVP, General Counsel

Sold at will

29,697

$62.96K

5.7%

ALLO Allogene Therapeutics, Inc.

2 Feb 2026

SVP, General Counsel

Sold at will

22,900

$40.30K

3.9%

ALLO Allogene Therapeutics, Inc.

3 Feb 2025

SVP, General Counsel

Sold at will

6,404

$10.95K

1.1%

3 decisions on file.